These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22748489)

  • 1. Circulating heart-type fatty acid binding protein levels predict the occurrence of appropriate shocks and cardiac death in patients with implantable cardioverter-defibrillators.
    Daidoji H; Arimoto T; Nitobe J; Tamura H; Kutsuzawa D; Ishigaki D; Ishino M; Takahashi H; Shishido T; Miyashita T; Miyamoto T; Watanabe T; Kubota I
    J Card Fail; 2012 Jul; 18(7):556-63. PubMed ID: 22748489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients.
    Niizeki T; Takeishi Y; Arimoto T; Takabatake N; Nozaki N; Hirono O; Watanabe T; Nitobe J; Harada M; Suzuki S; Koyama Y; Kitahara T; Sasaki T; Kubota I
    J Card Fail; 2007 Mar; 13(2):120-7. PubMed ID: 17395052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating heart-type fatty acid-binding protein levels predict ventricular fibrillation in Brugada syndrome.
    Daidoji H; Arimoto T; Iwayama T; Ishigaki D; Hashimoto N; Kumagai Y; Nishiyama S; Takahashi H; Shishido T; Miyamoto T; Watanabe T; Kubota I
    J Cardiol; 2016 Mar; 67(3):221-8. PubMed ID: 26058546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy.
    Komamura K; Sasaki T; Hanatani A; Kim J; Hashimura K; Ishida Y; Ohkaru Y; Asayama K; Tanaka T; Ogai A; Nakatani T; Kitamura S; Kangawa K; Miyatake K; Kitakaze M
    Heart; 2006 May; 92(5):615-8. PubMed ID: 16387818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing myocardial damage in patients with heart failure and preserved ejection fraction.
    Kutsuzawa D; Arimoto T; Watanabe T; Shishido T; Miyamoto T; Miyashita T; Takahashi H; Niizeki T; Takeishi Y; Kubota I
    J Cardiol; 2012 Dec; 60(6):454-61. PubMed ID: 22819040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction.
    Yu H; Oswald H; Gardiwal A; Lissel C; Klein G
    Am J Cardiol; 2007 Aug; 100(4):635-9. PubMed ID: 17697820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies.
    Verma A; Kilicaslan F; Martin DO; Minor S; Starling R; Marrouche NF; Almahammed S; Wazni OM; Duggal S; Zuzek R; Yamaji H; Cummings J; Chung MK; Tchou PJ; Natale A
    Heart; 2006 Feb; 92(2):190-5. PubMed ID: 15923278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
    O'Donoghue M; de Lemos JA; Morrow DA; Murphy SA; Buros JL; Cannon CP; Sabatine MS
    Circulation; 2006 Aug; 114(6):550-7. PubMed ID: 16880323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
    Olshansky B; Poole JE; Johnson G; Anderson J; Hellkamp AS; Packer D; Mark DB; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2008 Apr; 51(13):1277-82. PubMed ID: 18371559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
    Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
    Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
    N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators.
    Chen HA; Hsia HH; Vagelos R; Fowler M; Wang P; Al-Ahmad A
    Pacing Clin Electrophysiol; 2007 Mar; 30(3):390-4. PubMed ID: 17367359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction.
    Haltern G; Peiniger S; Bufe A; Reiss G; Gülker H; Scheffold T
    Am J Cardiol; 2010 Jan; 105(1):1-9. PubMed ID: 20102882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death.
    Mezu U; Adelstein E; Jain S; Saba S
    Am J Cardiol; 2011 Sep; 108(5):718-22. PubMed ID: 21640321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.